Aims/hypothesis A progressive loss of pancreatic beta cell function, a decrease in beta cell mass and accumulation of islet amyloid is characteristic of type 2 diabetes mellitus. The main constituent of islet amyloid is islet amyloid polypeptide (IAPP). In this study, we examined the ability of the peptidase neprilysin to cleave IAPP and prevent human IAPP-induced pancreatic beta cell toxicity. Methods Neprilysin and a catalytically compromised neprilysin mutant were tested for their ability to inhibit human IAPP fibrillisation and human IAPP-induced pancreatic beta cell cytotoxicity. Degradation of human IAPP by neprilysin was followed by HPLC, and the degradation products were identified by MS. . It also appears to prevent human IAPP fibrillisation through a non-catalytic interaction. Neprilysin protected against beta cell cytotoxicity induced by exogenously added or endogenously produced human IAPP. Conclusions/interpretation The data presented support a potential therapeutic role for neprilysin in preventing type 2 diabetes mellitus. This study supports the hypothesis that extracellular human IAPP contributes to human IAPPinduced beta cell cytotoxicity. Whether human IAPP exerts its cytotoxic effect through a totally extracellular mechanism or through a cellular reuptake mechanism is unclear at this time.
, Asn 22 -Phe 23 and Ala 25 -Ile 26 . It also appears to prevent human IAPP fibrillisation through a non-catalytic interaction. Neprilysin protected against beta cell cytotoxicity induced by exogenously added or endogenously produced human IAPP. Conclusions/interpretation The data presented support a potential therapeutic role for neprilysin in preventing type 2 diabetes mellitus. This study supports the hypothesis that extracellular human IAPP contributes to human IAPPinduced beta cell cytotoxicity. Whether human IAPP exerts its cytotoxic effect through a totally extracellular mechanism or through a cellular reuptake mechanism is unclear at this time. [1] . Both are characterised by functional tissue loss associated with accumulation and aggregation of a small peptide-islet amyloid polypeptide (IAPP, also known as amylin) in pancreatic islets in type 2 diabetes and amyloid β peptide (Aβ) in AD brain. Human IAPP (hIAPP) aggregation leads to pancreatic beta cell loss, while Aβ aggregation leads to neuronal cell loss [2, 3] . Similarly to the synthesis of Aβ from the amyloid precursor protein, IAPP is derived from an 89-residue prohormone precursor (prepro-IAPP) to form the mature 37-amino acid peptide hormone [4] . IAPP is co-secreted with insulin by pancreatic beta cells [5] [6] [7] . hIAPP, like human Aβ but not rodent IAPP (rIAPP) or rodent Aβ, forms oligomers and then fibrils leading to the amyloid deposits seen in association with type 2 diabetes and AD, respectively. In the case of IAPP it is thought that three proline residues within the region of amino acids 20-29 of rIAPP hinder its aggregation. hIAPP lacks these proline residues and aggregates under pathological circumstances [8] .
There are several cellular mechanisms to prevent hIAPP accumulation. The unfolded protein response is one such mechanism [2, 9] . Another is to prevent hIAPP accumulation via its degradation by peptidases analogous to the peptidasedependent clearance of Aβ in AD. An upregulation of synthesis and secretion or a downregulation of degradation may contribute to hIAPP accumulation and subsequent aggregation. To date, insulin-degrading enzyme is the only enzyme reported to be able to degrade IAPP [10] . Inhibition of this enzyme by bacitracin has been reported to impair IAPP degradation and accelerate amyloid formation in insulinoma cells [10, 11] . More recently, neprilysin (NEP), another amyloid-degrading enzyme, was demonstrated to be involved in the regulation of IAPP aggregation [12, 13] through what was proposed to be a non-catalytic mechanism. NEP has been shown to play a major role in the clearance of Aβ in brain [14] , and thus NEP playing a role in preventing IAPP aggregation would represent another parallel between type 2 diabetes and AD.
NEP has been reported to be present in both mouse and human pancreatic islets [13] . In experiments conducted in transgenic mice, inhibition of NEP increased amyloid formation [12] . Conversely, upregulation of NEP decreased amyloid formation and beta cell apoptosis in cultured hIAPP transgenic mouse islets [12] . However, since NEP degradation of hIAPP was not observed, it was suggested that NEP acted by inhibiting hIAPP fibrillisation through a non-catalytic protein-protein interaction [12] . In this study, we examined the ability of NEP to cleave hIAPP and prevent hIAPP-induced beta cell toxicity.
Methods
Materials IAPP (1-37, disulfide bridge 2-7, amide) was purchased from Anaspec (Fremont, CA, USA), dissolved in hexafluoride isopropanol and aliquoted. The hexafluoride isopropanol was then evaporated using a Speedvac (Thermo Scientific, Waltham, MA, USA), and the powder stored at −80°C. IAPP was freshly dissolved in DMSO (2.5 mmol/l) and diluted in the appropriate buffer or cell culture medium before use.
Cell culture reagents were from Invitrogen (Carlsbad, CA, USA). Adenoviruses expressing the genes for green fluorescent protein (GFP), prepro-rIAPP-GFP and preprohIAPP-GFP were prepared as previously described [15, 16] . Glutaryl-Ala-Ala-Phe-4-methoxy-2-naphthylamide (GAAF-4-MNA), hippuryl-L-phenylalanine and human transferrin (TF) were from Sigma (St Louis, MO, USA). For immunoblotting, rabbit anti-cleaved caspase-3 (Cell Signaling Technology, Danvers, MA, USA), mouse anti β-actin (EMD Chemicals, Gibbstown, NJ, USA) and rabbit anti-IAPP (Bachem, San Carols, CA, USA) were used.
Production and purification of recombinant NEP DNA encoding the ectodomain of human NEP or a catalytically compromised NEP E585V mutant (NEPx) was amplified from plasmid pCSC-SP-PW-NEP or pCSC-SP-PW-NEPx [17] by PCR using the following forward and reverse primers, respectively: 5′-TGAAGGATCCTACGATGATGGTATTTGC-3′, 5′-TCGAGCGGCCGCTCACCAAACCCGGCACTTCTT-3′. After confirmation by DNA sequencing, the PCR products were digested with BamHI/NotI and subcloned into the same sites of the expression vector psGHP1. The psGHP1 vector contains a human growth hormone (GH) domain and an octahistidine affinity tag [18] followed by a PreScission protease cleavage site into vector pLEXm [19] . Chinese hamster ovary (CHO)-derived suspension culture cells (CHO-S, Invitrogen) cells transfected with psGHP1-NEP or psGHP1-NEPx were cultured for 4 days, and the supernatant fraction was collected and concentrated with a Pellicon tangential flow filtration system (Millipore, Billerica, MA, USA). His-Tagged NEP or NEPx-human GH fusion proteins were purified using HIS-Select Nickel Affinity Gel (Sigma). GH was then removed by digestion with PreScission protease overnight at 4°C. The proteins were then applied to a MonoQ CEX anion-exchange column in 20 mmol/l Tris/HCl buffer (pH 7.4) and eluted with a 0-0.5 mol/l linear NaCl gradient. NEP was eluted at 0.15 mol/l NaCl. The NEP-containing fractions were pooled, concentrated with a Millipore Centricon concentrator, and stored at −80°C in 20% glycerol. The purity of recombinant proteins was determined using NIH Image J software [20] to analyse Coomassie blue-stained gels subjected to SDS-PAGE.
Fluorogenic assay of NEP activity NEP activity was determined with the fluorogenic substrate, GAAF-4-MNA [17] . Reaction mixtures (200 μl) contained 100 μmol/l GAAF-4-MNA, 1 μg recombinant puromycin-sensitive aminopeptidase (PSA) and 20 mmol/l 2-(N-morpholino)ethanesulfonic acid (MES) buffer, pH 6.5. Reactions were initiated by the addition of enzyme and monitored continuously at 37°C at an excitation wavelength of 340 nm and an emission wavelength of 425 nm using a SpectraMAX GeminiXS Microplate reader (Molecular Devices, Sunnyvale, CA, USA). In this assay, GAAF-4-MNA is cleaved by NEP to release F-4-MNA, which is then converted into the fluorescent 4-MNA by excess PSA [21] .
Carboxypeptidase activity assay Carboxypeptidase activity was determined using 100 μmol/l hippuryl-L-phenylalanine as substrate with the generation of hippuric acid monitored at 254 nm at 25°C [22] . The same concentration of NEP and the same buffer as was used in measuring NEP-dependent hIAPP degradation were used in this assay.
Thioflavin T assay The fibrillisation of hIAPP was monitored using thioflavin T as described previously with minor modifications [12] . hIAPP was dissolved in DMSO (2.5 mmol/l) and then diluted into 25 mmol/l Tris/HCl buffer, pH 8.0, containing 100 mmol/l NaCl to give a final concentration of 50 μmol/l hIAPP and 2% DMSO. A 1 μmol/l stock of recombinant human NEP or NEPx was prepared in the same buffer. Reactions were initiated by mixing equal amounts of the hIAPP stock with the NEP stock. In control experiments, 1 μmol/l NEP was preincubated with 50 μmol/l of the NEP inhibitor, phosphoramidon (PA), for 30 min. Preliminary experiments confirmed >99% inhibition of NEP activity under this condition. Reaction mixtures were placed in a 37°C incubator in the dark with gentle rocking for 20 h. Thioflavin T was added to the mixture to a final concentration of 5 μmol/l, and, after mixing, the fluorescence was measured at 437 nm excitation and 482 nm emission. BSA and TF were used as protein controls.
Transmission electron microscopy The fibrillisation of hIAPP was examined by transmission electron microscopy using samples at the end of the thioflavin T experiments (at t020 h) as previously described [12, 23] .
Cell culture The rat insulinoma cell line INS 832/13, kindly provided by Dr Christopher Newgard (Duke University, Durham, NC, USA) [24] , was cultured at 37°C and 5% CO 2 in RPMI 1640 medium supplemented with 11.1 mmol/l glucose, 10% FBS, 10 mmol/l HEPES, 2 mmol/l L-glutamine, 1 mmol/l sodium pyruvate, 50 μmol/l 2-mercaptoethanol and 100 U/ml penicillin plus 100 μg/ml streptomycin. For cytotoxicity studies, cells were treated with 20 μmol/l hIAPP and purified NEP or NEPx. Cytotoxicity was analysed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [25] as well as by measuring the cleavage and activation of caspase-3 [26, 27] , the key downstream enzyme in hIAPP-induced apoptosis in pancreatic beta cells [2, 27] . In another paradigm, cells were transduced with adenovirus expressing prepro-hIAPP-GFP at a multiplicity of infection (MOI) of 100 and cultured for 48 h. Adenovirus expressing GFP and prepro-rIAPP-GFP at the same MOI were used as controls. Cell cytotoxicity was analysed as above.
MTT assay For determining cell viability, an MTT stock solution (5 mg/ml in PBS) was added at 1:10 (vol./vol.) dilution to the culture medium. After incubation in the dark at 37°C for 4 h, the supernatant fraction was removed and 0.4 mol/l HCl in isopropanol (1 culture volume) was added. The plates were kept in the dark at room temperature for 1 h, and then the absorbance at 570 nm was measured. Cell viability was calculated as the percentage of the absorbance of experimentally treated cells compared with the absorbance of a vehicle control [25] .
Western blot analysis Protein concentration was determined using the BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). Cell lysates containing 25 μg total protein were separated on a 4-12% Bis-Tris NuPAGE gel (Invitrogen) and transferred to polyvinylidine difluoride membranes (BioRad, Hercules, CA, USA). Membranes were blocked and incubated overnight at 4°C with one of the following primary antibodies: rabbit anti-cleaved caspase-3 (1:1,000), rabbit anti-IAPP (1:3,000) and mouse anti-β-actin (1:10,000). Membranes were washed with Tris-buffered saline/0.1% Tween 20, incubated with the corresponding horseradish peroxidaseconjugated secondary antibody (Zymed Laboratories, San Francisco, CA, USA), followed by ECL-Plus (GE Healthcare, Piscataway, NJ, USA) detection. Protein production levels were quantified using NIH ImageJ software [20] . Membranes were reprobed after stripping.
Cleavage of hIAPP by NEP hIAPP (20 μmol/l) was incubated with NEP or NEPx in 20 mmol/l MES buffer, pH 6.5, at 37°C. Reactions were stopped by the addition of trifluoroacetic acid (TFA) to 0.5% and then analysed by reverse-phase HPLC on a Vydac C4 column. Fractions were separated by a linear gradient from 0.1% TFA in 90% water/10% acetonitrile to 0.1% TFA in 50% water/ 50% acetonitrile [28] . hIAPP or its cleavage products were collected manually and identified by MS using an Applied Biosystems 4800 MALDI TOF/TOF (matrixassisted laser desorption/ionization time-of-flight/timeof-flight) Proteomics Analyzer (Life Technologies, Carlsbad, CA, USA). In addition, reaction mixtures, after being stopped with TFA and bound to and eluted from a C18 mini column, were analysed directly in the mass spectrometer.
Statistical analysis Data were expressed as mean±SEM and compared using one-way ANOVA followed by Dunnett's multiple comparison test for statistical significance. Values with p<0.05 are considered significant.
Results
Effect of NEP and NEPx on hIAPP fibrillisation Recombinant human NEP and NEPx were produced as their secreted catalytic ectodomain using CHO-S cells and purified by Ni-affinity chromatography and anionexchange chromatography. The calculated molecular mass of the NEP ectodomain is 83 kDa, while its apparent molecular mass on SDS-PAGE is about 95 kDa because of its glycosylation. NEP purity was >95% as judged by Coomassie blue staining of an SDS-PAGE gel, while that of NEPx was~80% (Fig. 1a) . The major contamination in the NEPx preparation was bovine TF, molecular mass of 75 kDa, which was identified by MALDI TOF/TOF. As noted below, TF had no effect on hIAPPinduced cytotoxicity. NEP and NEPx activities were determined using the fluorogenic substrate, GAAF-4-MNA (Fig. 1b) . The E585V mutation abolished >98% of the NEP activity, as previously reported [29] . The NEP inhibitor, PA, reduced the activity of NEP and NEPx to undetectable levels (Fig. 1b) .
We initially sought to confirm and extend the report that NEP impedes islet amyloid formation by inhibition of fibril formation through protein-protein interactions [12] . Thus the ability of the NEPx and active NEP to inhibit hIAPP fibril formation was compared. NEPx retained the same substrate-binding affinity as NEP [29] , while, as noted above, losing >98% of its enzymatic activity. This form of NEP, like NEP itself, should be capable of preventing hIAPP fibrillisation through protein-protein interactions. We measured hIAPP fibrillisation in the presence of either 0.5 μmol/l NEP or NEPx as described by Zraika et al [12] . Fibrillisation was monitored at various time points to obtain a complete picture of the kinetics of the process. NEP or NEPx treated with 50 μmol/l PA or the same molar concentration of BSA or TF served as controls. As shown in Fig. 2a , hIAPP had undergone fibrillisation after 6 h, reaching a maximum after 9 h as indicated by the increase in thioflavin T fluorescence. TF, BSA, PA-inhibited NEP and PA-inhibited NEPx all delayed hIAPP fibrillisation, as thioflavin T fluorescence did not increase until 9 h, but reached the same maximum as the untreated control after 12 h. We interpret this effect to represent a non-specific inhibitory effect of protein on hIAPP fibrillogenesis. In contrast, NEP completely inhibited hIAPP fibril formation over the entire 20 h incubation period. However, the addition of the same amount of NEPx delayed hIAPP fibrillisation slightly more than BSA or TF, indicating a contribution of its residual activity.
To exclude the possibility that the added proteins or PA interfered with the thioflavin T assay [23] , electron microscopy was used to confirm fibril formation at the 20 h time point. As shown in Fig. 2b , hIAPP fibrils were observed in the untreated hIAPP (CTRL), NEPx and TF samples. Fibrils were also seen in BSA, PA-treated NEP and PA-treated NEPx samples (data not shown). In contrast, fibrils were not seen with NEP-treated hIAPP.
NEP cleaves hIAPP in vitro
The ability of NEP to prevent hIAPP fibrillisation and the absence of an effect of catalytically compromised NEPx suggests that NEP impedes islet amyloid formation by degrading hIAPP. We thus tested the ability of NEP to cleave hIAPP by incubating 20 μmol/l hIAPP with 400 nmol/l NEP or NEPx at 37°C for 1 h. Reactions were terminated by the addition of TFA to a final concentration of 0.5% and then analysed by reversephase HPLC. As shown in Fig. 3a , the hIAPP peak had decreased more than 70% after the 1 h incubation period and a number of product peaks were observed. hIAPP cleavage was blocked by the NEP inhibitor, PA (Fig. 3b) . In addition, no cleavage of hIAPP was observed with NEPx under identical reaction conditions (Fig. 3c) , clearly demonstrating that NEP cleaves hIAPP.
To identify the NEP cleavage sites, hIAPP was incubated with NEP at 37°C for 60 min, and products were separated by HPLC. Peaks were manually collected and subjected to MS analysis for identification. Cleavage of hIAPP by NEP was detected at Arg 11 (Fig. 4) . The C-terminal product of the Ala 25 -Ile 26 cleavage (ILSSTNVGSNTY-NH 2 ) appeared to be further cleaved, as this product initially increased with time, but then decreased at later times (Fig. 5a ). The two major products were the N-terminal peptides hIAPP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] and hIAPP [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] (peaks 4 and 7 in the HPLC chromatogram, Fig. 4a ). We were unable to identify peaks 1-3 (Fig. 4a) . We confirmed cleavage sites by directly Fig. 1 Purified recombinant NEP and NEPx. (a) Recombinant NEP and NEPx were purified by nickel affinity and anion-exchange chromatography as described in the Methods section and analysed by SDS-PAGE on a 10% polyacrylamide gel stained with Coomassie blue. The purity of recombinant NEP was >95%, while the purity of recombinant NEPx was~80%. The 75 kDa protein contaminant in the NEPx preparation was identified as bovine TF by MALDI TOF/TOF. (b) Activity of recombinant NEP, NEPx, NEP in the presence of PA, and NEPx in the presence of PA as determined with GAAF-4-MNA as substrate. NEPx exhibited~1.7% of wild-type NEP activity. PA decreased NEP and NEPx activity to undetectable levels measuring the reaction products by MS without prior separation by HPLC. Additional products, KCNTATCATQRLANF, KCNTATCATQRLANFLVHSSNNFGA, KCNTATCATQR LANFLVHSSNN and LANFLVHSSNNFGAILSSTNB GSNTY-NH 2 , were found by direct analysis. All of these cleavage sites are consistent with the known specificity of NEP, which cleaves on the amino side of non-polar residues [30] . 26 in hIAPP, which is probably attributable to the amino acid differences between rat and human IAPP. As four of the cleavage products were clustered together, we considered the possibility that these may be derived by secondary cleavage by a contaminating carboxypeptidase acting on KCNTATCATQRLANF. We thus assayed for carboxypeptidases activity in the NEP preparations, but no such activity was detected.
Comparison of NEP cleavage of hIAPP with that of Aβ 1-40 Since Aβ 1-40 is a well-known substrate for NEP [14, 31, 32] , we compared its degradation with that of hIAPP. Rates of peptide hydrolysis were determined by measuring the disappearance of the hIAPP or Aβ 1-40 peak by HPLC (Fig. 5a, b) . The logarithm of the percentage of substrate remaining was plotted as a function of time for the linear range (Fig. 5c) Effect of exogenous NEP and NEPx on hIAPP-induced cytotoxicity of pancreatic beta cells The effects of recombinant NEP or NEPx on hIAPP-induced cytotoxicity were examined using the INS 832/13 insulinoma cell line. Cells were treated with hIAPP in the presence of NEP or NEPx, and cell viability was determined 48 h after treatment using the MTT assay. As shown in Fig. 6a , there were 15.6±3.5% viable cells after treatment for 48 h with 20 μmol/l hIAPP relative to vehicle control cells (CTRL). In contrast, rIAPP did not cause significant cytotoxicity. The addition of 400 nmol/l or 40 nmol/l NEP blocked hIAPP-induced cytotoxicity (84.5 ± 7.3% viable cells in the presence of 400 nmol/l NEP and 92.9±9.5% viable cells in the presence of 40 nmol/l NEP), while 4 nmol/l NEP increased the cell viability to 39.4±15.3%, although statistical significance was not reached. In contrast, only 400 nmol/l NEPx significantly increased cell viability (58.4±9.3%). The addition of 400 nmol/l TF to the culture medium did not protect beta cells against hIAPP-induced cytotoxicity. In addition, the effect of NEP on hIAPP-induced apoptosis was evaluated by measuring the cleavage and activation of caspase-3 [26, 27] , the key downstream enzyme in hIAPP-induced apoptosis in pancreatic beta cells [2, 27] . hIAPP, but not rIAPP, induced apoptosis in INS 832/13 cells, as indicated by the increase in cleaved caspase-3 (Fig. 6b) . The ratio of cleaved caspase-3/actin induced by hIAPP decreased by 67% and 95% with 40 nmol/l or 400 nmol/l NEP, respectively. To further study the effect of NEP on hIAPP-induced cytotoxicity, the precursor to hIAPP, prepro-hIAPP, was expressed in INS 832/13 cells. Cells were transduced with adenovirus expressing prepro-hIAPP fused with a GFP tag at an MOI of 100 [26] . As previously reported [26] and confirmed in Fig. 7b , prepro-IAPP-GFP is processed by prohormone convertases PC1/3 and PC2 to form mature IAPP in INS 832/13 cells. As controls, cells were treated with the same MOI of adenovirus expressing prepro-rIAPP-GFP or GFP. The MTT assay and cleaved caspase-3 levels were measured to determine the effects of recombinant NEP and NEPx on the hIAPP overproduction-induced beta cell cytotoxicity. As shown in Fig. 7a , overproduction of hIAPP, but not rIAPP or GFP, induced cytotoxicity in INS 832/13 cells. The addition of 400 nmol/l NEP reduced this hIAPPinduced cytotoxicity, but lower concentrations of NEP, NEPx or TF had no effect. Furthermore, overproduction of hIAPP, but not rIAPP or GFP, by adenovirus transduction induced apoptosis, as indicated by an increase in cleaved caspase-3 (Fig. 7b) . Addition of NEP to the medium dramatically decreased the amount of activated caspase-3. The normalised ratio of cleaved caspase-3/actin was decreased by 28%, 59% and 78% with 4, 40 or 400 nmol/l recombinant NEP, respectively. For NEPx, only 400 nmol/l NEPx treatment reduced hIAPP induced apoptosis. No effect on hIAPPinduced apoptosis was observed with cells treated with 4 or 40 nmol/l NEPx or 400 nmol/l TF (Fig. 7c) .
Discussion
In the present study, the ability of NEP and NEPx to inhibit hIAPP fibrillisation and hIAPP-induced cytotoxicity were compared. NEPx retains the same substrate binding affinity as wild-type NEP [29] , while, as noted above, losing >98% of its enzymatic activity. NEP completely prevented hIAPP Fig. 4 Identification of NEP cleavage sites in hIAPP. hIAPP (20 μmol/l) was incubated with 400 nmol/l recombinant NEP at 37°C for 60 min. TFA was then added to 0.5% to stop the reaction, which was then subjected to HPLC. Products were collected manually and subjected to MS analysis for identification. (a) HPLC chromatograms of hIAPP incubated with NEP (t00 min) and after incubation at 37°C for 60 min (t060 min). The insert shows the identified degradation products as determined by MS. (b) Schematic representation of the cleavage sites on hIAPP. Thick arrows indicate the major cleavage sites, while thin arrows indicate minor cleavage sites. Reaction products were confirmed and further extended by direct infusion of a reaction mixture into the mass spectrometer. The solid line under the hIAPP sequence represents digestion products identified by both HPLC and direct infusion of the reaction mixture, while the dashed line represents digestion products identified only by HPLC, and the dotted line represents digestion products identified only by direct infusion. a These products contained oxidised cysteines at positions 2 and 7 fibril formation, as measured by both thioflavin T binding and electron microscopy. NEPx delayed fibrillisation, but did not completely inhibit hIAPP fibrillisation in what appears to be primarily a non-specific effect of the protein.
The concentration of catalytically compromised NEPx required to prevent insulinoma cell cytotoxicity by hIAPP, either added to cells or produced through overproduction of the precursor, was much higher than that of active NEP, consistent with the major effect of NEP being through degradation of hIAPP.
We have shown that NEP degrades hIAPP, although slowly compared with Aβ. This differs from the study of Zraika et al [12] in which it was concluded that NEP did not cleave hIAPP. In that study, NEP was shown to degrade Aβ but not IAPP. However, since NEP cleaves Aβ 30 times faster than hIAPP (Fig. 5c) , it is quite possible that Zraika et al used sufficient NEP to observe Aβ cleavage, but insufficient NEP to observe IAPP cleavage.
Taken together, these data suggest that there are two mechanisms whereby NEP can block hIAPP fibril formation. The first is a non-catalytic mechanism, as proposed by Zraika et al [12] , in which NEP interacts with hIAPP through undefined non-specific protein-protein interactions. That this effect is non-specific is supported by the finding that both TF and BSA are as effective as inactive (PAtreated) NEP in inhibiting fibril formation. In addition, relatively high protein concentrations are required to see this effect. The second mechanism whereby NEP blocks hIAPP fibril formation is through catalytic cleavage. The latter mechanism is in keeping with the ability of NEP to degrade Aβ [14, 31, 32] , another fibril-forming peptide.
Previous studies have suggested that NEP is present and active in both human and mouse islets and may play a role in regulating islet amyloid accumulation [12, 13] . Thus, much like the role of NEP in preventing amyloid accumulation in AD, NEP may prevent hIAPP aggregation in pancreatic beta cells. Hence NEP-based therapeutic strategies for preventing type 2 diabetes are worthy of consideration.
Whether the toxic species of hIAPP are formed intracellularly or extracellularly, or both, remains ambiguous. Initially, it was thought that hIAPP co-secreted with insulin could aggregate extracellularly to form oligomers and then fibrils, leading to mature amyloid deposits [33] . These insoluble mature hIAPP amyloid deposits were thought to cause pancreatic beta cell loss, as amyloid deposits were found in the majority of individuals with type 2 diabetes [34] [35] [36] . Furthermore, the extent of extracellular amyloid deposition correlated with beta cell apoptosis and beta cell loss [37] as well as clinical severity of diabetes [38] . However, several more recent studies suggest that it is soluble hIAPP oligomers rather than insoluble amyloid deposits that represent the cytotoxic species [2, [39] [40] [41] [42] [43] . It has been proposed that hIAPP aggregation starts intracellularly [2, 44] , since hIAPP oligomers were detected intracellularly in beta cells of hIAPP transgenic mice [40, 41] as well as in individuals with type 2 diabetes [41] . Since vaccine-induced high titres of antibodies to hIAPP oligomers in transgenic mice failed to prevent, but instead exacerbated, beta cell apoptosis and diabetes onset, it was suggested that hIAPP-induced toxicity in hIAPP transgenic mice is probably initiated intracellularly and that this intracellular IAPP may not be accessible to oligomer antibodies [40] .
How intracellular hIAPP accumulates and aggregates remains a key question. A recent study suggested that exogenous hIAPP could be internalised by beta cells, a process regulated by plasma membrane cholesterol levels [45] . The finding in the present study that NEP added to the cell medium prevents hIAPP-induced apoptosis from endogenously produced hIAPP shows that, at least in a cell model, extracellular hIAPP contributes to hIAPP-induced death. Since exogenous NEP would not be able to enter cells, this shows that extracellular hIAPP secreted by INS 832/13 cells plays a role in hIAPP-induced apoptosis. This is consistent with a previous report showing that hIAPP release is necessary for islet amyloid formation and its toxic effects [46] . It is interesting that islet beta cells are reportedly more susceptible to extracellular hIAPP toxicity than cultured alpha cells [27] ; however, additional studies are required to verify the underlying mechanism. Unfortunately, these results do not distinguish between hIAPP aggregating extracellularly and inducing cell death and hIAPP being secreted, re-entering the cells, and inducing cell death. In both cases, extracellular NEP reduces the concentration of extracellular IAPP and thus would affect either process.
Taken together, the results of this study demonstrate the hIAPP-degrading activity of NEP and its protective effects against hIAPP-induced pancreatic beta cell apoptosis. This study highlights the potential of enzymatically degrading extracellular hIAPP as a therapeutic approach for type 2 diabetes. 
